Regencell Bioscience's 15min Chart Shows Bullish Signals with Golden Cross, Marubozu Candlestick Patterns.

As of 10/06/2025 at 15:15, Regencell Bioscience's 15-minute chart has triggered a KDJ Golden Cross and a Bullish Marubozu, indicating a shift in momentum towards the upside and potential for further price appreciation. Buyers currently dominate the market, and it is likely that bullish momentum will continue.

As of September 12, 2025, Regencell Bioscience Holdings Limited (NASDAQ: RGC), a Hong Kong-based biopharmaceutical company specializing in Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders such as ADHD and autism spectrum disorder (ASD), has shown encouraging technical indicators. The 15-minute chart for Regencell Bioscience triggered a KDJ Golden Cross and a Bullish Marubozu, signaling a shift in momentum towards the upside and potential for further price appreciation Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results^[1].

The KDJ Golden Cross occurs when the K line crosses above the D line, indicating a bullish trend. The Bullish Marubozu pattern, characterized by a long white candle with no shadows, suggests strong buying pressure and a potential breakout. Currently, buyers dominate the market, and it is likely that bullish momentum will continue.

Regencell Bioscience's stock has experienced significant volatility, with a notable peak in mid-2025, driven by speculative trading, a stock split, and excitement over trial results. Despite these challenges, the company reported positive results from its second efficacy trial, showing a mean symptom improvement of 37% with no adverse side effects for ADHD and ASD treatments. However, no FDA-approved products have been announced yet, and the treatments remain investigational.

On the fundamental side, Regencell Bioscience continues to face challenges, including zero revenue, ongoing losses, and uncertain regulatory pathways for its treatments. Nonetheless, its inclusion in the S&P Global BMI Index in September 2025 may enhance liquidity and help stabilize the stock Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results^[1].

While the potential of RGC as an investment is acknowledged, certain AI stocks offer greater upside potential and carry less downside risk. Investors should be cautious and conduct thorough due diligence before making any investment decisions.